Medicine and HealthBlood Cancer Journal
Economic Burden of Disease Progression in Multiple Myeloma Patients Receiving Stem Cell Transplant
R. Fonseca, M. Hagiwara, et al.
This research, conducted by Rafael Fonseca, May Hagiwara, Sumeet Panjabi, Emre Yucel, Jacqueline Buchanan, and Thomas Delea, reveals significant insights into healthcare resource utilization and costs for multiple myeloma patients post-stem cell transplant. The findings underscore the financial implications of disease progression, highlighting increased hospitalizations and varying costs across treatment lines.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation
M. S. Zinter, C. C. Dvorak, et al.
Medicine and Health
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
A. Medina, N. Puig, et al.
Medicine and Health
Current and projected future economic burden of Parkinson's disease in the U.S.
W. Yang, J. L. Hamilton, et al.
Medicine and Health
Global prevalence of diet low in calcium and the disease burden: results from the Global Burden of Disease Study 2019
G. Ti, Y. He, et al.
